NIH Budget Maintains Doubling Momentum

The drive to double spending by the National Institutes of Health between 1998 and 2003 reached its halfway point Dec. 15, when Congress approved a new NIH budget that represented a 50 percent increase from just three years ago. A 14 percent boost of $2.5 billion propels NIH spending to $20.3 billion for fiscal year 2001. The support expressed by President-elect George W. Bush during the presidential campaign to double NIH spending signals that the agency remains on track to double its budget in

Written byTom Hollon
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

The drive to double spending by the National Institutes of Health between 1998 and 2003 reached its halfway point Dec. 15, when Congress approved a new NIH budget that represented a 50 percent increase from just three years ago. A 14 percent boost of $2.5 billion propels NIH spending to $20.3 billion for fiscal year 2001. The support expressed by President-elect George W. Bush during the presidential campaign to double NIH spending signals that the agency remains on track to double its budget in just five years. The increase for 2001 far exceeds the Clinton administration's requested 5.6 percent addition of $1 billion and marks the third 14 percent hike in a row. Acting NIH director Ruth Kirschstein had called the first two increases in 1998 and 1999 "unprecedented" and the increase proves again the bipartisan popularity in Congress for medical research.

Generosity, however, doesn't mean timeliness as Congress once ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies